Citicoline vs Alpha-GPC
Affiliate disclosure: The Sourcing Standards section contains two affiliate links to products I use. If you buy through them, NeuroEdge Formula earns a commission at no extra cost to you. This version corrects several claims the previous one got wrong — including the size of Alpha-GPC’s landmark trial and a bioavailability comparison that doesn’t hold. Those corrections weaken the case for the compound I’d been favouring.
⚕️ Educational Information, Not Medical Advice
This article is educational and is not medical advice. I’m a cognitive enhancement researcher, not a medical doctor. Both compounds act on cholinergic neurotransmission and may not suit everyone. Alpha-GPC is a prescription pharmaceutical in much of Europe — check your jurisdiction. Consult a qualified healthcare provider before supplementing, particularly with cardiovascular risk factors, anticholinergic medications, or a pre-existing neurological condition.
Citicoline vs Alpha-GPC: Different Pathways, Different Evidence
By Peter Benson, Cognitive Enhancement Researcher | 18+ Years Independent Research · Last reviewed & citations re-verified: July 2026
Citicoline or Alpha-GPC is the question I get more than any other in the choline category, and the useful answer isn’t a winner. These are chemically distinct compounds running through different metabolic routes, with evidence bases built in different populations for different purposes. Treating the comparison as picking between two brands of the same thing produces protocol decisions that serve neither goal well.
I need to open with a correction, because this article previously carried several claims that don’t survive checking. It described Alpha-GPC’s landmark trial as enrolling 2,044 patients in an open-label study — it enrolled 261, and it was double-blind and placebo-controlled. It cited a pharmacokinetic study as proof of superior oral bioavailability when that study used intramuscular injection. And it attributed a citicoline trial to the wrong journal, the wrong year, and the wrong cognitive endpoint. All are fixed below, and the corrections matter: they narrow the gap between these two compounds considerably.
What follows is the mechanism of each, what the trials actually enrolled and measured, the TMAO question, and how I’d now frame the choice. For the compound-specific detail, see the full Alpha-GPC guide; for the wider cholinergic picture, the Nootropics & Supplements guide.
Mechanisms: genuinely different compounds
Alpha-GPC — direct choline delivery
Alpha-GPC is a phospholipid carrying roughly 40% choline by weight, against citicoline’s ~18%. It’s absorbed intact, crosses the blood-brain barrier, and releases choline for acetylcholine synthesis. As a phospholipid it can also incorporate into neuronal membranes — a genuine secondary role.
Here’s the correction that matters most in this comparison. The study cited everywhere — including in the previous version of this article — to prove Alpha-GPC’s superior bioavailability over citicoline is Gatti and colleagues’ comparison of free plasma choline following intramuscular administration (Gatti et al., 1992). Injecting a compound bypasses digestion and first-pass liver metabolism entirely. It tells you almost nothing about what happens when you swallow a capsule. The 40%-versus-18% figure is a real chemical fact; the claim that this translates into demonstrably superior oral delivery is an inference nobody has tested head-to-head.
Citicoline — choline plus a cytidine route
Citicoline (CDP-choline) is hydrolysed into cytidine and choline. The choline half follows the same acetylcholine pathway. The cytidine half converts to uridine, which feeds the CDP-choline cycle producing phosphatidylcholine — the principal phospholipid of neuronal membranes. That second route is citicoline’s distinctive contribution, and it’s the mechanistic basis for its use in neurological recovery, where membrane repair rather than neurotransmitter supply is the objective.
Cytidine and uridine have also been reported to support dopaminergic signalling, which is often cited as explaining citicoline’s effects on motivation and mental energy. I’d flag that this rests largely on preclinical work — plausible, mechanistically coherent, and not established in humans to the standard of the membrane-synthesis account.
The trials, described accurately
Alpha-GPC — Alzheimer’s
De Jesus Moreno Moreno (2003) — 261 patients
A multicentre, double-blind, randomised, placebo-controlled trial in mild-to-moderate Alzheimer’s dementia. 261 patients were enrolled — 132 on choline alfoscerate, 129 on placebo — at 400mg three times daily for 180 days, with ADAS-Cog, MMSE and GDS assessed at baseline, 90 and 180 days. Cognitive measures improved significantly versus placebo, with good tolerability (De Jesus Moreno Moreno, 2003).
Two corrections: the previous version of this article said 2,044 patients and described the study as open-label. Both were wrong. 261 is a respectable trial, and double-blind placebo-controlled is better methodology than open-label — but it is not the largest cholinergic trial ever run, and I should not have implied otherwise.
Alpha-GPC — healthy adults
Kerksick (2024) — 20 resistance-trained men
A randomised, double-blind, placebo-controlled crossover in which 20 resistance-trained males received placebo, 315mg or 630mg, with Stroop, N-Back and Flanker testing 60 minutes later (Kerksick, 2024). It found improvement versus placebo, most clearly on the Stroop measure. The previous version described this as “a single 600mg dose in healthy men” — the doses were 315 and 630mg, the sample was twenty, and all were resistance-trained. It’s the best acute evidence available in a non-impaired population, and it’s small.
Citicoline — neurological recovery
Dávalos (2002) — pooled patient-level analysis
An individual patient data pooling analysis of oral citicoline trials in acute ischaemic stroke, reporting improved recovery outcomes versus placebo (Dávalos et al., 2002). The previous version called this “a randomised, placebo-controlled trial” — it is a pooled analysis across trials, which is a different and in some respects stronger form of evidence, but should be labelled correctly. This is the domain where citicoline’s membrane-repair mechanism has its clearest clinical support, and where Alpha-GPC has no equivalent.
Citicoline — healthy adults
McGlade (2012) — attention in 60 women
A double-blind, randomised, placebo-controlled three-arm study in which 60 healthy women aged 40–60 received 250mg citicoline, 500mg, or placebo daily for 28 days, assessed on the Continuous Performance Test II (McGlade et al., 2012, Food and Nutrition Sciences). Attentional performance improved versus placebo.
Three corrections here. The previous version cited this as Journal of Nutrition 2015 with a PMID belonging to a different paper — it is Food and Nutrition Sciences, 2012, 3:769–773. It described the outcome as “memory and attention”; the endpoint was attention, measured by CPT-II. And the author list includes staff of Kyowa Hakko, which manufactures Cognizin® — the branded citicoline this article goes on to recommend. That industry affiliation should be disclosed rather than omitted, exactly as I disclose it for the Alzheimer’s-trial equivalents elsewhere on this site.
Evidence hierarchy
Regraded in this revision. Several rows were previously green on evidence that doesn’t support it.
The TMAO question
Dietary choline is metabolised by gut bacteria into trimethylamine, which the liver oxidises into TMAO. Elevated plasma TMAO has been associated with increased cardiovascular risk in large observational studies. Because both compounds are choline sources, this pathway applies to both — but Alpha-GPC’s higher choline content per dose means it loads that pathway more heavily.
Stated honestly: this is an association in observational data, not demonstrated causation. TMAO production varies enormously between individuals depending on gut microbiome composition, and the cardiovascular risk from 300–600mg of Alpha-GPC daily in an otherwise healthy adult has never been quantified.
The previous version of this article attributed this to “a 2021 study in the European Heart Journal” with no citation attached. I’ve removed that attribution rather than leave an unverifiable claim standing. The underlying pathway is well described in the metabolic literature; the specific study reference was not one I could substantiate.
Practically: for healthy adults under 50 with no cardiovascular risk factors, this warrants awareness rather than avoidance. Over 50, or with hypertension, dyslipidaemia or family history of cardiovascular disease, citicoline is the more defensible choice — and given that no oral head-to-head has ever shown Alpha-GPC’s cognitive superiority, you’re giving up less than the marketing implies. Our nootropic safety guide covers how to weigh signals like this generally.
🧮 Worked example — choosing between them, step by step
Rather than “which is better,” run the decision in this order — each step can settle it before you reach the next:
1. Any cardiovascular risk? (over 50, hypertension, high cholesterol, family history) → citicoline, and you can stop here. Its lower choline load is the deciding factor, and you’re not sacrificing proven cognitive benefit to get it.
2. Recovering from a neurological event, or membrane-repair the goal? → citicoline. This is the one domain with a clear evidence separation — the cytidine/phosphatidylcholine route, supported by the pooled stroke analysis.
3. Healthy, under 50, and want an acute same-session lift for a demanding day? → Alpha-GPC is reasonable, dosed situationally at 300mg active. This is where its acute crossover evidence is most relevant.
4. Just want one daily choline source and don’t fit the above? → default to citicoline. Broader mechanism, lower TMAO load, no prescription-status issues, and healthy-adult evidence at least as good. Notice that three of four branches land on citicoline — that’s the honest shape of the evidence once the bioavailability myth is removed.
Named Protocol
The NeuroEdge Dual Choline Protocol
Citicoline daily, Alpha-GPC situationally. Stated plainly: this combination has never been trialled as a combination. It’s a reasoned arrangement based on differing mechanisms, not an evidenced protocol.
Daily — Citicoline
250mg. The dose that produced attentional improvement in the 28-day trial, and the lower TMAO load. Cognizin® is the studied branded form.
Situational — Alpha-GPC
300mg active on high-demand days. With 50% products, confirm whether the label figure is active compound or total powder before dosing.
Cardiovascular risk — citicoline only
Over 50, or with hypertension, dyslipidaemia or family history: use citicoline alone, 250–500mg daily. Given no proven oral superiority for Alpha-GPC, the trade is smaller than it appears.
If you only want one
Start with citicoline. Broader mechanism, lower TMAO load, no prescription complications, and healthy-adult evidence at least as good as Alpha-GPC’s.
Peter’s Testing Notes
First-person, n=1 — reported honestly
I ran Alpha-GPC first, at 300mg active, and the impression was immediate and specific: sharper working memory recall in the first hour or so, and a motivation quality I’d describe as engaged rather than aroused — noticeably different from caffeine. Later I ran citicoline for twelve weeks with no other cholinergic compound. The acute effect in week one was much subtler. By weeks eight to twelve, what I noticed wasn’t a lift but a steadiness — less variability in how sharp I felt, particularly on short-sleep days.
I need to be careful about how much that’s worth. Neither phase was blinded. I knew which compound I was taking and what I expected from each, and the sequence — Alpha-GPC first, citicoline second — means any novelty effect favoured Alpha-GPC and any accumulated familiarity favoured citicoline. A previous version of these notes described my Creyos scores holding up “significantly better” on citicoline during deliberately shortened sleep; I’ve removed that framing, both because “significantly” implies a statistical test I never ran, and because deliberately restricting my own sleep to test a supplement is not a methodology I’d recommend to a reader.
My current arrangement is citicoline daily with Alpha-GPC on demanding days. Writing this rebuild has shifted my confidence, though. When the bioavailability comparison turns out to rest on an intramuscular study, and the landmark trial turns out to be a quarter of the size I’d been citing, the honest conclusion is that I preferred Alpha-GPC partly on evidence that wasn’t there. I still take it. I’d no longer tell anyone it’s the clearly superior compound.
Sourcing standards
For Alpha-GPC: the compound is strongly hygroscopic, so the 50% form is standard for capsule stability and is equivalent at matched active doses. Confirm which figure the label states. For citicoline: Cognizin® is the branded form used in most published trials — worth specifying, with the caveat that its manufacturer has co-authored some of that research.
Alpha-GPC — Nootropics Depot
Stable 50% form with published third-party testing and clearly stated active content. Label transparency is the reason I use it — this is a compound that’s easy to under-dose by half if you misread the figure.
Mind Lab Pro — Cognizin® citicoline 250mg
Carries citicoline at the 250mg dose used in the healthy-adult trial, with every dose in the formula disclosed. The option if you want the citicoline layer inside a broader stack rather than standalone.
Both compounds are sometimes stacked with phosphatidylserine, huperzine A or Bacopa as a “cholinergic stack.” None of those combinations has been tested as a combination — see the stacking guide for why that matters.
Key takeaways
| → | Alpha-GPC’s landmark trial enrolled 261 patients in a double-blind RCT — not 2,044, and not open-label. |
| → | Alpha-GPC’s superior oral bioavailability is not established — the comparison usually cited used intramuscular injection. |
| → | Citicoline’s distinct value is the cytidine route into membrane phosphatidylcholine synthesis, with clinical support in stroke recovery that Alpha-GPC lacks. |
| → | Healthy-adult evidence is thin for both: n=20 resistance-trained men for Alpha-GPC, n=60 women on an attention endpoint for citicoline. |
| → | If choosing one, start with citicoline — lower TMAO load, broader mechanism, and no proven cognitive disadvantage. |
Frequently asked questions
Is citicoline the same as Alpha-GPC?
No. Both supply choline, but through different routes with different downstream effects. Alpha-GPC is roughly 40% choline by weight and releases it for acetylcholine synthesis. Citicoline is roughly 18% choline, but its cytidine fraction converts to uridine and feeds phosphatidylcholine synthesis — the structural phospholipid of neuronal membranes. That second pathway is why citicoline has clinical evidence in stroke recovery that Alpha-GPC does not. They are complementary rather than interchangeable.
Is Alpha-GPC more bioavailable than citicoline?
It contains more choline by weight — around 40% versus 18% — which is a chemical fact. But the study routinely cited to prove superior bioavailability administered both compounds intramuscularly, bypassing digestion and first-pass liver metabolism entirely. That tells you very little about oral capsules. No head-to-head oral comparison has established that Alpha-GPC delivers more usable choline to the brain in practice. Treat the content difference as real and the delivery advantage as unproven.
Should I worry about Alpha-GPC and TMAO?
It’s an open question rather than a settled risk. Gut bacteria convert dietary choline to TMA, which the liver oxidises to TMAO, and elevated TMAO has been associated with cardiovascular risk in observational research. Alpha-GPC’s higher choline content loads that pathway more than citicoline does. But association is not causation, individual conversion rates vary greatly with gut microbiome composition, and the risk at supplemental doses has never been quantified. For healthy adults under 50 this warrants awareness; over 50 or with cardiovascular risk factors, citicoline is the more defensible option.
Can I take citicoline and Alpha-GPC together?
You can, and the differing mechanisms make it a reasonable arrangement — but be clear that the combination has never been tested as a combination. Any claim about what the pair does together is inference, not evidence. If you do run both, keep total doses moderate rather than doubling each, and introduce them one at a time so you can attribute any effect. Watch total choline intake, since both feed the same TMAO pathway.
Which should I choose if I only want one?
Citicoline, for most people. It has a broader mechanism, a lower TMAO load, no prescription-status complications, and healthy-adult evidence at least as good as Alpha-GPC’s — 60 women over 28 days on an attention measure, versus 20 resistance-trained men in a single acute session. Alpha-GPC makes more sense if you specifically want an acute, same-session effect on a demanding day, and you have no cardiovascular risk factors. Neither is well-established for cognitive enhancement in healthy adults, and honest expectations should reflect that.
Get “7 Days to a Sharper Brain” — Free
Peter Benson’s personal daily protocol, rebuilt from 18 years of testing
Seven evidence-based interventions, in the exact order that makes each one more effective — from sleep foundation to your complete assembled daily stack.
Join 2,000+ readers optimising their cognitive performance. Unsubscribe anytime.
Scientific references
1. De Jesus Moreno Moreno, M. (2003). Cognitive improvement in mild to moderate Alzheimer’s dementia after treatment with the acetylcholine precursor choline alfoscerate: A multicenter, double-blind, randomized, placebo-controlled trial. Clinical Therapeutics, 25(1), 178–193. PMID: 12637119
2. Kerksick, C. M. (2024). Acute alpha-glycerylphosphorylcholine supplementation enhances cognitive performance in healthy men. Nutrients, 16(23), 4240. PMID: 39683633 · PMC11644786
3. McGlade, E., Locatelli, A., Hardy, J., Kamiya, T., Morita, M., Morishita, K., Sugimura, Y., & Yurgelun-Todd, D. (2012). Improved attentional performance following citicoline administration in healthy adult women. Food and Nutrition Sciences, 3, 769–773. DOI: 10.4236/fns.2012.36103 (Note: co-authored by staff of Kyowa Hakko, manufacturer of Cognizin®.)
4. Dávalos, A., et al. (2002). Oral citicoline in acute ischemic stroke: An individual patient data pooling analysis of clinical trials. Stroke, 33(12), 2850–2857. PMID: 11835408
5. Gatti, G., Barzaghi, N., Acuto, G., Abbiati, G., Fossati, T., & Perucca, E. (1992). A comparative study of free plasma choline levels following intramuscular administration of L-alpha-glycerylphosphorylcholine and citicoline in normal volunteers. Int J Clin Pharmacol Ther Toxicol, 30(9), 331–335. PMID: 1428296
6. National Institutes of Health, Office of Dietary Supplements. Choline: Fact Sheet for Health Professionals. ods.od.nih.gov
Peter Benson
Cognitive Enhancement Researcher | 18+ Years Independent Research
Peter has tested both compounds across four years. This guide was substantially rebuilt after re-verifying its source literature — including correcting a trial size, a study design, a route of administration, and a journal attribution that were all previously wrong. He is not a clinician; this is educational, not medical advice.
Last reviewed: July 2026
